Total Funding
79
12
Total FundingConvertible Note raised
Growth Score 79 in past quarter
-6 pts
Heat Score 12 in past quarter
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
153226
CompagOs is developing a blood-based test to help oncologists detect bone metastases early with mineralized bone models.
About the Company
Our mission is to help oncologists select the most effective treatment for patients with cancer in the bone. Leveraging 3D bioprinting technology, we recreate the unique cancerous condition of the patient's bone in a controlled laboratory environment, enabling us to assess different drug reactions and determine personalized treatment options.
By surpassing the limitations of conventional animal and 2D models, we also envision our solution as a powerful tool for drug development, accurately reproducing human physiological conditions and driving innovation in the field. Together, we aim to revolutionize cancer treatment by offering personalized solutions that improve patient outcomes and advance the field of oncology.